CAMBRIDGE, Mass. (May 22, 2012) Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 ...

A combination of three drugs used worldwide as the standard of care for a serious lung disease puts patients in danger of death or hospitalization, and should not be used together to treat the disease, called idiopathic pulmonary fibrosis, according to the surprising results of a rigorous independent study...

(Whitehead Institute for Biomedical Research) A clinical trial involving collaboration between researchers at Whitehead Institute and Dana Farber Cancer Institute is now enrolling patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer. In the developed world, approximately two-thirds of all breast cancer cases are ER+. The trial will test ...

By Randy Dotinga HealthDay Reporter WEDNESDAY, May 16 (HealthDay News) -- A preliminary, first-stage study funded by a pharmaceutical company shows promising results for an experimental double-drug therapy for melanoma. The two drugs, known as dabrafenib and trametinib, appeared to delay ...

By Amanda Gardner HealthDay Reporter TUESDAY, May 15 (HealthDay News) -- A two-drug combination that relieves migraines in adults also works well in adolescents, new research indicates. Although the findings basically support what doctors are already doing, "it is nice to have ...

A combination of two diabetes drugs, metformin and rosiglitazone, was more effective in treating youth with recent-onset type 2 diabetes than metformin alone, a study funded by the National Institutes of Health (NIH) has found. Adding an intensive lifestyle intervention to metformin provided no more benefit than metformin therapy alone. ...

Controlling blood sugar in children and teenagers with diabetes type two is best achieved with a metformin plus rosiglitazone combo, compared to just metformin or metformin plus lifestyle changes, researchers reported in NEJM (New England Journal of Medicine). Blood-sugar control is also known as glycemic control, or blood glucose ...

THURSDAY, April 19 (HealthDay News) -- It's not clear whether patients with type 2 diabetes gain any long-term benefit from taking the blood sugar-lowering drug metformin and insulin together rather than insulin alone. That's the conclusion of Danish researchers who reviewed data from 23 clinical trials involving more ...

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was evaluated using a measure termed progression-free survival (PFS). According to the results of a ...

TUESDAY, April 3 (HealthDay News) -- Adding the drug cetuximab (brand name Erbitux) to standard chemotherapy after surgery for stage 3 colon cancer did not improve disease-free survival in patients, a new study concludes. Patients with stage 3 colon cancer who undergo surgery have a 50 percent chance of ...

(Mayo Clinic) The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found.

A new analysis of research evidence suggests that one of the AIDS drug regimens increasingly used in developing countries and recommended by the World Health Organization (WHO), may have an unacceptably high risk of failure and rate of drug resistance in patients. The study, led by the Stanford ...